# Piers Ingram

> Piers Ingram is a Singapore-based British scientist and entrepreneur who co-founded Hummingbird Bioscience and Callio Therapeutics with Jerome Boyd-Kirkup. Trained in mathematics, bioinformatics and systems biology at Imperial College London, with an INSEAD MBA, he worked in academia, Monitor Group consulting and Sanofi regional strategy before company founding. He remains Hummingbird CEO and became a Callio senior advisor in September 2026 while continuing on its board.

- **Role:** Co-founder and Senior Advisor at Callio Therapeutics; Co-founder and CEO at Hummingbird Bioscience
- **Organizations:** Callio Therapeutics, Hummingbird Bioscience, Sanofi, Monitor Group, Imperial College London
- **Nationality:** British
- **Education:** MSci in Mathematics, Imperial College London, MSc in Bioinformatics, Imperial College London, PhD in Systems Biology, Imperial College London, MBA, INSEAD
- **Known for:** Co-founded Hummingbird Bioscience in Singapore in 2015., Received INSEAD Alumni Emerging Entrepreneur Award in the 2019/2020 cycle., Led Hummingbird during its US$125 million Series C financing in 2021.

## Career timeline

- **2008-2010** — Research fellow, then acting research group head at Imperial College London’s Centre for Integrative Systems Biology.
- **2011** — Completed INSEAD MBA, class MBA’11J.
- **2011-2013** — Manager in Monitor Group’s strategy consulting practice.
- **2013-2015** — Head of Strategic Planning, Southeast Asia, at Sanofi.
- **2015** — Co-founded Hummingbird Bioscience with Jerome Boyd-Kirkup.
- **2019-2020** — Named INSEAD Alumni Emerging Entrepreneur Award recipient for the 2019/2020 cycle.
- **2021** — Hummingbird closed a US$125 million Series C led by Novo Holdings.
- **2022** — Hummingbird opened its 40,000-square-foot Singapore Science Park facility.
- **2025** — Co-founded Callio Therapeutics as founding CEO; company launched with a US$187 million Series A.
- **2026-09** — Transitioned to Callio senior advisor while retaining board membership and continuing as Hummingbird CEO.

## Achievements

- Co-founded Hummingbird Bioscience in Singapore in 2015.
- Received INSEAD Alumni Emerging Entrepreneur Award in the 2019/2020 cycle.
- Led Hummingbird during its US$125 million Series C financing in 2021.
- Led Hummingbird when it opened a 40,000-square-foot Singapore facility in 2022.
- Co-founded Callio, which launched with a US$187 million Series A in March 2025.
- Hummingbird, the company he co-founded and leads, was one of ten WIPO Global Awards winners in 2025; this is a company award.

## Latest updates

- **2026-09** — Callio appointed Zachary Hornby CEO on September 9; Ingram became Senior Advisor and retained his board seat, while continuing as Hummingbird CEO.

## Links

- LinkedIn: https://www.linkedin.com/in/piersingram/

---

Profile page: https://yespress.io/piers-ingram
Published by YesPress — https://yespress.io
Last updated: 2026-10-15